Rob Hallford joined Duke’s Office of Licensing & Ventures in 2010, bringing more than 15 years of experience in the pharmaceutical and life science venture capital industries. Most recently, Rob served as Vice President of Business Development for Nanosyn, where he led sales efforts for their contract biology services. Prior to Nanosyn, as a Senior Associate at Pappas Ventures, he sourced, evaluated and managed venture capital investments, working closely with several portfolio companies, including a role as Director of Business Development for CoLucid Pharmaceuticals. Rob also worked for eight years with Eli Lilly and Company, where he held positions in Lilly Ventures, Corporate Strategy and Business Development, Research Portfolio Management, and Biopharmaceutical Development. During his tenure at Lilly, Rob operated on a number of business development deal teams and co-developed the global product development strategy for Lilly's $2 billion diabetes business. Hallford received his BS and MS in chemistry from Furman University and his MBA from Duke University’s Fuqua School of Business.